FDA approved a new use for Lymphoseek Injection (technetium 99m tilmanocept), a radioactive diagnostic imaging agent, to determine the extent squamous cell carcinoma has spread in the body's head and neck region.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
A dendritic cell-based immunotherapeutic vaccine increased median overall survival by about four months in a phase II placebo-controlled study in newly diagnosed glioblastoma multiforme.
In a phase III trial of patients with progressive radioiodine-refractory differentiated thyroid cancer, lenvatinib significantly extended progression-free survival compared to placebo.
A phase III trial demonstrated a 37 percent improvement in progression-free survival when using the investigational compound LBH589 (panobinostat) in combination with bortezomib and dexamethasone compared to treatment with the same regimen with placebo in patients with relapsed or relapsed and refractory multiple myeloma.
Data from the phase III RESONATE trial showed that monotherapy ibrutinib significantly lengthened progression-free survival and overall survival compared to ofatumumab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia.
By priming pancreatic ductal adenocarcinomas with a therapeutic vaccine and a low-dose chemotherapy combination prior to surgery, researchers converted PDACs into cancers that may respond to immunotherapy.
A drug used to treat men with late-stage prostate cancer proved effective in stemming progression of the disease in research participants who had not yet received chemotherapy and extended their survival, according to results from a multi-national phase III clinical trial
New overall survival data of two phase III clinical trials, LUX-Lung 3 and LUX-Lung 6, demonstrated that patients with advanced non-small cell lung cancer whose tumors have the most common epidermal growth factor receptor mutation lived longer if treated with first-line afatinib compared to chemotherapy.
From left to right: Eddie Reed, then-NCI Director Sam Broder, and Brawley in 1991. Reed was receiving an award for his role in developing Taxol.Reed, 60, had liver cancer. Many of us will remember Eddie for his achievements. They were many and spectacular. In the late 1980s, I was the other and younger Black doctor in the Medicine Branch at NCI. I will remember him as a cancer doc, an intense man with high standards.
